Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 6, 2026

Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?

Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio? Gilead Sciences, Inc…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

The FDA approval has the potential to establish Trodelvy as a new standard of care in first-line mTNBC, expanding its use beyond the second-line setting.
60% confidence